ArticleAntimicrobial agents and chemotherapy2020
Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions.
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Clinical Considerations of Amikacin Pharmacotherapy in Adults-A Narrative Review with Focus on Safety and TDM.Antibiotics (Basel, Switzerland) · 2026Review
- Therapeutic Drug Monitoring-Based Population Pharmacokinetics of Amikacin in Patients at a Teaching Hospital.Antibiotics (Basel, Switzerland) · 2025Article
- Failure to predict amikacin elimination in critically ill patients with cancer based on the estimated glomerular filtration rate: applying PBPK approach in a therapeutic drug monitoring study.European journal of clinical pharmacology · 2023Article
- Individualized antibiotic dosage regimens for patients with augmented renal clearance.Frontiers in pharmacology · 2023Review
- Prevalence and Risk Factors of Augmented Renal Clearance: A Systematic Review and Meta-Analysis.Pharmaceutics · 2022Review
- Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation.Pharmaceutics · 2022Article
- Synthesis, biological activities and docking studies of pleuromutilin derivatives with piperazinyl urea linkage.Journal of enzyme inhibition and medicinal chemistry · 2021Article
- Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?Antibiotics (Basel, Switzerland) · 2021Review
- Population Pharmacokinetics Analysis of Amikacin Initial Dosing Regimen in Elderly Patients.Antibiotics (Basel, Switzerland) · 2021Article
- Augmented Renal Clearance: What Have We Known and What Will We Do?Frontiers in pharmacology · 2021Review
- Population Pharmacokinetic Analysis of Amikacin for Optimal Pharmacotherapy in Korean Patients with Nontuberculous Mycobacterial Pulmonary Disease.Antibiotics (Basel, Switzerland) · 2020Article
- Urinary Creatinine Clearance and Pharmacokinetics Studies: If We Can Measure It, Why Do We Estimate It?Antimicrobial agents and chemotherapy · 2020Article
- Augmented Renal Clearance and How to Augment Antibiotic Dosing.Antibiotics (Basel, Switzerland) · 2020Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this work was to evaluate the pharmacokinetics of amikacin in Mexican patients with different renal functions receiving once-daily dosing regimens and the influence of clinical and demographical covariates that may influence the optimization of this antibiotic. A prospective study was performed in a total of 63 patients with at least one determination of amikacin plasma concentration. Population pharmacokinetic (PK) parameters were estimated by nonlinear mixed-effects modeling; validations were performed for dosing recommendation purposes based on PK/pharmacodynamic simulations. The concentration-versus-time data were best described by a one-compartment open model with proportional interindividual variability associated with amikacin clearance (CL) and volume of distribution (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.